Cargando…
Determinants of drug expenditure in the Swiss healthcare market in 2006
BACKGROUND: Several measures are in force in Switzerland to control the cost of drugs, but are not effective enough. There are many determinants influencing these expenditures, related to treatments, markets, physicians, patients and regions, but their impact on costs is not clear. METHODS: We appli...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264585/ https://www.ncbi.nlm.nih.gov/pubmed/35799160 http://dx.doi.org/10.1186/s12913-022-08212-x |
_version_ | 1784742995102269440 |
---|---|
author | Eggli, Yves Decollogny, Anne Piaget-Rossel, Romain Taffé, Patrick |
author_facet | Eggli, Yves Decollogny, Anne Piaget-Rossel, Romain Taffé, Patrick |
author_sort | Eggli, Yves |
collection | PubMed |
description | BACKGROUND: Several measures are in force in Switzerland to control the cost of drugs, but are not effective enough. There are many determinants influencing these expenditures, related to treatments, markets, physicians, patients and regions, but their impact on costs is not clear. METHODS: We applied a Bayesian multilevel model with five levels to adjust for patients, drugs’ market, and physicians ‘characteristics, treatment type, and district (i.e. Swiss canton). We used data of the Swiss drugs’ market in 2006, offering real choices for doctors and patients (multiple products for similar active substances), with a neutral position of pharmacists (no financial incentives). RESULTS: Variance partitioning of yearly drugs’ cost per insured showed that market level (delivered substance) contributed to 76% of the variance, treatment level (delivered product) to 20%, whereas patients’ and physicians’ levels accounted for only 2% each, without significant differences between Swiss cantons. After adjusting for covariables at each level, the model explained about 51% of the variation at the market and 20% at the treatment levels. We found that older but substitutable drugs, generics, larger size of the market and physician’s specialty were associated with lower expenditure, whereas drugs requiring a physician’s prescription, the number of prescribers per patient, patient’ age, male gender, and comorbidities increased expenditure. Our results show that for a specific medication the yearly cost of recently released drugs was 36 CHF higher than for similar and substitutable drugs introduced 15 years earlier, corresponding to one third of the average annual treatment cost observed in our dataset. Competition did not seem to be effective to reduce expenditure on the drug market. CONCLUSION: The main finding of this study is that recentness of drugs was associated with an increase in drug expenditure in 2006, even after adjustment for all non-controllable determinants. Further research is recommended to confirm those results with updated data. |
format | Online Article Text |
id | pubmed-9264585 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-92645852022-07-09 Determinants of drug expenditure in the Swiss healthcare market in 2006 Eggli, Yves Decollogny, Anne Piaget-Rossel, Romain Taffé, Patrick BMC Health Serv Res Research BACKGROUND: Several measures are in force in Switzerland to control the cost of drugs, but are not effective enough. There are many determinants influencing these expenditures, related to treatments, markets, physicians, patients and regions, but their impact on costs is not clear. METHODS: We applied a Bayesian multilevel model with five levels to adjust for patients, drugs’ market, and physicians ‘characteristics, treatment type, and district (i.e. Swiss canton). We used data of the Swiss drugs’ market in 2006, offering real choices for doctors and patients (multiple products for similar active substances), with a neutral position of pharmacists (no financial incentives). RESULTS: Variance partitioning of yearly drugs’ cost per insured showed that market level (delivered substance) contributed to 76% of the variance, treatment level (delivered product) to 20%, whereas patients’ and physicians’ levels accounted for only 2% each, without significant differences between Swiss cantons. After adjusting for covariables at each level, the model explained about 51% of the variation at the market and 20% at the treatment levels. We found that older but substitutable drugs, generics, larger size of the market and physician’s specialty were associated with lower expenditure, whereas drugs requiring a physician’s prescription, the number of prescribers per patient, patient’ age, male gender, and comorbidities increased expenditure. Our results show that for a specific medication the yearly cost of recently released drugs was 36 CHF higher than for similar and substitutable drugs introduced 15 years earlier, corresponding to one third of the average annual treatment cost observed in our dataset. Competition did not seem to be effective to reduce expenditure on the drug market. CONCLUSION: The main finding of this study is that recentness of drugs was associated with an increase in drug expenditure in 2006, even after adjustment for all non-controllable determinants. Further research is recommended to confirm those results with updated data. BioMed Central 2022-07-07 /pmc/articles/PMC9264585/ /pubmed/35799160 http://dx.doi.org/10.1186/s12913-022-08212-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Eggli, Yves Decollogny, Anne Piaget-Rossel, Romain Taffé, Patrick Determinants of drug expenditure in the Swiss healthcare market in 2006 |
title | Determinants of drug expenditure in the Swiss healthcare market in 2006 |
title_full | Determinants of drug expenditure in the Swiss healthcare market in 2006 |
title_fullStr | Determinants of drug expenditure in the Swiss healthcare market in 2006 |
title_full_unstemmed | Determinants of drug expenditure in the Swiss healthcare market in 2006 |
title_short | Determinants of drug expenditure in the Swiss healthcare market in 2006 |
title_sort | determinants of drug expenditure in the swiss healthcare market in 2006 |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264585/ https://www.ncbi.nlm.nih.gov/pubmed/35799160 http://dx.doi.org/10.1186/s12913-022-08212-x |
work_keys_str_mv | AT eggliyves determinantsofdrugexpenditureintheswisshealthcaremarketin2006 AT decollognyanne determinantsofdrugexpenditureintheswisshealthcaremarketin2006 AT piagetrosselromain determinantsofdrugexpenditureintheswisshealthcaremarketin2006 AT taffepatrick determinantsofdrugexpenditureintheswisshealthcaremarketin2006 |